Cerebrolysin 120mg Nasal Spray

Description

This cerebrolysin nasal spray supplies a peptide preparation produced from purified porcine brain protein by enzymatic breakdown. Composition is reported as approximately 80 percent low-molecular-weight peptides, generally under 10 kDa, and 20 percent free amino acids. The single most important thing to understand before designing an experiment with it is that this is not a molecule. It is a mixture defined by its manufacturing process, and that distinction governs everything from how you cite it to how you compare two lots. Supplied for laboratory research use only.

A mixture, not a compound, and why that changes your methods section

Every other product in this catalogue has a sequence, a molecular weight and a CAS number. This one does not, because it is not a single chemical entity. What it has instead is a manufacturing process and a specification.

That has direct consequences at the bench. You cannot report a molar concentration, because there is no single molecular weight to divide by, so exposures are expressed by mass or volume per unit of medium. You cannot verify identity by mass spectrometry the way you would for a synthetic peptide, because the expected result is a complex spectrum rather than one peak. And a purity percentage means something different here: for a mixture, the meaningful question is compositional consistency between lots, not the proportion of one desired species.

The practical rule that follows is the one I would put above everything else on this page. Use a single lot for an entire study, record the lot number in your methods, and treat a lot change as a protocol change requiring re-baselining. For a synthetic peptide that advice is good practice. For a process-defined biological mixture it is the difference between a reproducible experiment and an uninterpretable one.

The proposed mode of action, and the vocabulary around it

The mechanistic case made for this peptide mixture is that it behaves like the body’s own neurotrophic factors. The named ones in that family are brain-derived neurotrophic factor, usually written BDNF, nerve growth factor or NGF, glial cell line-derived neurotrophic factor or GDNF, and ciliary neurotrophic factor, CNTF, collectively abbreviated NTF in some of the literature. The claim is that a preparation of porcine brain proteins broken into short peptides and amino acids can supply comparable neurotrophic support, with the fragments themselves described as neurotrophic peptides, which is why marketing calls it a multi-modal neuropeptide drug rather than a single-target agent. Manufacturer material from Ever Pharma sets out that mode of action, sometimes abbreviated MOA.

The mechanisms invoked underneath it are the standard ones in this field: neuroprotection and neuroprotective effects against excitotoxicity, an anti-inflammatory effect measured as dampened neuroinflammation and lower pro-inflammatory cytokines, reduction of oxidative stress, support for neurogenesis and neuroplasticity including synaptic plasticity at existing synapses, axonal sprouting, myelination, angiogenesis, and preservation of the neurovascular unit and the blood-brain barrier. Each of those is measurable in a cell or slice model, and treating the list as a description of demonstrated activity rather than a set of hypotheses is where most writing about this compound goes wrong.

A note on the surrounding categories. This preparation is given intravenously or by intramuscular injection, written IM injection on most protocols, in the jurisdictions where it is used clinically, so the route of administration in that setting is not nasal, and neurorehabilitation is the context those courses sit in. Separately, it turns up in nootropic discussion alongside compounds such as Semax, Selank, Dihexa and NAD, framed around cognitive enhancement, mental clarity, brain fog and memory loss. Those are consumer descriptions rather than endpoints, none of them is established for this material, and none is claimed here. Regenerative medicine is likewise a field, not a property of a bottle.

What the clinical evidence actually shows

Cerebrolysin is used clinically in Russia, Eastern Europe, China and several post-Soviet countries, mainly in acute ischaemic stroke, and it is not approved by the FDA. Clinical use in some jurisdictions gets quoted as though it settles the efficacy question. The systematic review evidence says otherwise.

The Cochrane review Cerebrolysin for acute ischaemic stroke concluded from moderate-quality evidence that it probably has little or no beneficial effect on preventing all-cause death in acute ischaemic stroke, and little or no effect on the total number of people experiencing serious adverse events. The review also reported moderate-quality evidence of an increase in non-fatal serious adverse events. The review has been updated since, most recently in 2023, and the direction has not reversed.

It is worth knowing what those trials measured, because the endpoints are standardised and you can check them yourself. Acute ischemic stroke work reports the NIH stroke scale, abbreviated NIHSS, as a severity score, and the modified Rankin scale or mRS as the measure of functional recovery and disability afterwards. Trials in traumatic brain injury use related functional scales, and the CARS trial is the frequently cited study in the stroke and neurorehabilitation literature for this compound. Beyond stroke and TBI, the wider clinical programme has covered Alzheimer’s disease, vascular dementia and cognitive impairment more generally, with cognitive decline and cognitive function as the endpoints. Those are the neurological conditions the compound has been studied in, and citing the studies is different from citing a result.

That is the current best synthesis of the randomized evidence, and it is a null-to-negative result from the most methodologically conservative source in the field. It does not make the preparation uninteresting as a research material, since a complex mixture of brain-derived peptides is a legitimate thing to study in vitro. It does mean any page presenting this as an established neuroprotective treatment is ahead of the evidence.

Intranasal cerebrolysin research and in-vitro models

Intranasal cerebrolysin research exists in the animal literature, motivated by the general observation that the nasal route can deliver molecules toward the central nervous system while partly avoiding first-pass metabolism. Two cautions belong with that. Nose-to-brain transport is far better established for small lipophilic molecules than for peptide mixtures, and rodent nasal anatomy differs enough from human that route comparisons across species need care. Nothing about this material’s supplied format constitutes guidance for administration to anything.

For cell work, the readouts that suit a neurotrophic-type preparation are neurite outgrowth and branching in primary neurons or differentiated neuronal lines, survival under a defined stressor such as oxygen-glucose deprivation or excitotoxic challenge, and expression of neuronal maturation markers. The design point specific to a mixture is the control: a vehicle control alone is insufficient, because the material contains 20 percent free amino acids and an amino acid load by itself can alter cell behaviour. A matched free-amino-acid control is what separates a peptide effect from a nutritional one, and its absence is the most common weakness in this literature.

Cerebrolysin nasal spray specifications

Identity data for this cerebrolysin peptide nasal spray. Note the deliberate absence of a sequence, molecular weight and CAS number, which is a property of the material rather than a gap in the listing.

Cerebrolysin nasal spray storage and handling

Two considerations here are specific to a biologically sourced mixture rather than to a synthetic peptide.

The first is endotoxin. Material of animal origin carries a realistic possibility of bacterial endotoxin contamination, and endotoxin is a potent activator of inflammatory signalling in cultured cells at concentrations far below anything that would look like a problem. If your readout touches NF-kB, cytokine output, microglial activation or anything immune-adjacent, endotoxin content is not an optional line on a certificate, it is a confound waiting to be misread as an effect. Ask for it explicitly.

The second is compositional drift. Peptide mixtures can change with time and temperature in ways a single peptide does not, because different components degrade at different rates, so the ratio between them shifts even while total mass stays similar. Proper cerebrolysin nasal spray storage means cold, sealed, out of light, and single-use aliquots rather than repeated freeze-thaw cycles on one container. Record how long a working solution has been open, because with a mixture the composition, not just the concentration, is what ages.

How research grade cerebrolysin spray is characterized

Honesty is more useful than reassurance here. A research grade cerebrolysin spray cannot be verified the way a synthetic peptide can. There is no single mass to confirm and no meaningful purity percentage, so the questions worth asking a supplier are different: what the source material is, what the process specification is, whether peptide size distribution is characterized, whether total peptide and free amino acid content are quantified, and what the endotoxin result is. At PrymaLab, research materials are supplied with the analytical documentation available for that material, and independent third-party testing is used across the range. No specific lot figures are asserted on this page; request the certificate of analysis for the lot you receive, and for this material read it with the mixture questions above in mind rather than looking for a purity number that would not mean much.

For related neurological research compounds, see the PrymaLab Research Library.

Frequently asked questions

What is Cerebrolysin?

It is a peptide preparation made from purified porcine brain protein by enzymatic processing, reported as roughly 80 percent low-molecular-weight peptides under 10 kDa and 20 percent free amino acids. It is a process-defined mixture rather than a single molecule. Material supplied here is for in-vitro laboratory use only.

Why does this cerebrolysin peptide nasal spray have no CAS number?

Because CAS numbers identify defined chemical substances, and this material is a mixture of many peptides plus free amino acids. For the same reason there is no single molecular weight, so exposures are reported by mass or volume rather than molarity.

What does the clinical evidence show?

The Cochrane review of acute ischaemic stroke found moderate-quality evidence of probably little or no effect on all-cause death, and moderate-quality evidence of an increase in non-fatal serious adverse events. It is used clinically in some countries, which is not the same as demonstrated efficacy.

What controls does a Cerebrolysin experiment need?

A vehicle control plus a matched free-amino-acid control, because the material is about 20 percent free amino acids and an amino acid load alone can change cell behaviour. Endotoxin testing matters too if your readout involves inflammatory or immune signalling.

Is cerebrolysin nasal spray approved for human use?

No. This material is a research chemical for in-vitro laboratory use only and is not intended for human or veterinary use. It has no FDA approval. Its use as a medicine in other jurisdictions has no bearing on research-chemical material. Nothing here is medical advice.

Ordering and compliance

Every PrymaLab research compound ships from the United States and is sold research-use-only. This cerebrolysin nasal spray is supplied for in-vitro laboratory research, is not intended for human or veterinary use, is not a drug or supplement, and has not been evaluated by the FDA for the research-chemical context. Material of animal origin should be handled with appropriate biosafety precautions. Verify the legal status of any research compound in your jurisdiction before ordering. Certificates of analysis are available on request for the lot you receive.